AXS25 DigitalGuide V2 04.18 pages - Flipbook - Page 20
TUESDAY, APRIL 29
3:00 PM - 3:40 PM
Mouton 1
How the “Patient-as-Payer” Era Is Transforming Patient Access &
Affordability
John Daly, Sanofi; Helmuth Fendel, AbbVie; Dorothy Gemmell, GoodRx;
Jennifer Norton, Takeda; John M. O’Brien, National Pharmaceutical Council (NPC)
3:00 PM - 3:40 PM
Mouton 2
Beyond Logistics: The Strategic Edge of Specialty Distributors
PJ Argawal, Pfizer; Natalie Bedford, McKesson; Colin Russi, ZS Associates;
John B. Vernon, AstraZeneca
4:00 PM - 4:40 PM
Lafite 2
The State of Patient Access: The Hurdles to Commercial Success in
2025 and Beyond
Hannah Baxter, The Dedham Group; Steve Callahan, MMIT
4:00 PM - 4:40 PM
Margaux 1
Value / Outcome-Based Specialty Contracting - Where We Are, Where
We’re Headed and What is the Endpoint/Outcome?
Nancy Bell, Celuity; John M. O’Brien, National Pharmaceutical Council (NPC);
Kent Rogers, EveryONE Medicines / ARCH Venture Partners;
Roxie Schwans, Prime Therapeutics; Jayson Slotnik, Health Policy Strategies;
Burt Zweigenhaft, Association of Value Based Cancer Care / FFF Enterprises
4:00 PM - 4:40 PM
Margaux 2
Cell and Gene Therapies Improve Outcomes and Even Cure Diseases –
So Why is Commercial Uptake Slow?
Rocky Billups, HCA Healthcare; Joe DePinto, McKesson; Dan Kirby, Iovance
4:00 PM - 4:40 PM
Mouton 1
It Takes a Network: Tackling Affordability Together
Srulik Dvorsky, TailorMed; Marianne Gandee, Pfizer;
Tracey James, Walgreens Specialty Pharmacy; Ebony McCroskey, MetroHealth;
Molly MacDonald, The Pink Fund
4:00 PM - 4:40 PM
Mouton 2
The Current State of Rare Disease Therapeutics in the Payer Landscape
Jeffrey D. Dunn, Cooperative Benefits Group; Stephen Meninger, Alnylam
Pharmaceuticals; Sean Quinn, OptumRx; Zach Romaine, Express Scripts
4:30 PM - 6:30 PM
Sunset Pool, Wynn
Cocktails & Conversation
* as of March 29, 2025
20 I DIGITAL GUIDE
